What antibiotic regimen is recommended for resistant Gram‑negative bacilli infections based on the infected organ site and drug penetration?

Organ Site-Specific Antibiotic Selection for Resistant Gram-Negative Infections

For resistant Gram-negative infections, antibiotic selection must be tailored to the infected organ site based on drug penetration characteristics, with newer β-lactam/β-lactamase inhibitor combinations preferred for most sites, while polymyxins and aminoglycosides require site-specific consideration due to poor tissue penetration.

Respiratory Tract Infections (HAP/VAP)

For Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)

• First-line: Ceftolozane-tazobactam (excellent lung penetration) 12
• Alternative for severe DTR-PA pneumonia: Most active β-lactam/β-lactamase inhibitor combination PLUS aerosolized colistin or aminoglycosides 1
• For metallo-β-lactamase producers: Cefiderocol combined with fosfomycin, plus aerosolized colistin or aminoglycosides 12

For Carbapenem-Resistant Acinetobacter baumannii (CRAB)

• Sulbactam-susceptible: Ampicillin-sulbactam 3
• Sulbactam-resistant: Polymyxin or high-dose tigecycline (if active in vitro) 3
• Combination therapy strongly suggested: Two in vitro active antibiotics (polymyxin, aminoglycoside, tigecycline, sulbactam combinations) for severe infections 3

For Carbapenem-Resistant Enterobacterales (CRE)

• Preferred: Ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam 4
• For metallo-β-lactamase producers: Cefiderocol or aztreonam-avibactam 4

Bloodstream Infections (BSI)

For CRAB

• Recommended: Ampicillin-sulbactam PLUS colistin 1
• Alternative: Cefiderocol 4

For KPC-Producing Enterobacterales

• First choice: Meropenem-vaborbactam 1
• Alternative: Ceftazidime-avibactam 4

For CRPA

• Preferred: Ceftolozane-tazobactam, ceftazidime-avibactam, or imipenem-relebactam 34
• Severe infections: Consider combination therapy with two active agents 3

Urinary Tract Infections (cUTI)

For ESBL-Producing Enterobacterales

• If piperacillin-tazobactam MIC ≤8 mg/L: High-dose piperacillin-tazobactam with loading dose and continuous infusion 1
• Alternative: Carbapenems (if susceptible)

For AmpC-Producing Enterobacterales (excluding Enterobacter spp.)

• If cefepime MIC ≤2 mg/L: High-dose cefepime 1

For CRE

• Preferred: Newer β-lactam combinations (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) 4
• Note: These agents achieve excellent urinary concentrations, making monotherapy often sufficient for cUTI 3

Intra-Abdominal Infections (IAI)

For Third-Generation Cephalosporin-Resistant Enterobacterales

• Recommended: Ceftolozane-tazobactam OR ceftazidime-avibactam PLUS metronidazole 1

For Metallo-β-Lactamase-Producing Enterobacterales

• Recommended: Ceftazidime-avibactam PLUS aztreonam PLUS metronidazole 1
• Rationale: Aztreonam provides activity against metallo-β-lactamase producers while avibactam protects it from other β-lactamases

Central Nervous System Infections

For CRPA

• Recommended: Ceftazidime-avibactam PLUS fosfomycin 1
• Rationale: Both agents achieve adequate CSF penetration, particularly with meningeal inflammation

Critical Pharmacokinetic Considerations by Site

Poor Penetration Sites Requiring Dose Optimization:

• CNS: Avoid polymyxins (poor CSF penetration); prefer β-lactams with dose optimization
• Lung tissue: Polymyxins benefit from aerosolized administration; β-lactams require high-dose extended infusions 55
• Prostate: Avoid aminoglycosides and polymyxins; fluoroquinolones or fosfomycin preferred (when susceptible)

Excellent Penetration Sites:

• Urinary tract: Most antibiotics achieve high concentrations; monotherapy often sufficient for non-severe infections 3
• Bile: Tigecycline, piperacillin-tazobactam achieve good biliary concentrations

Combination Therapy Principles

For severe/high-risk infections, combination therapy with two in vitro active agents is strongly suggested 355:

• Polymyxin-based combinations: Strongly recommended over monotherapy (strong recommendation, moderate evidence) 55
• Avoid: Polymyxin-rifampin and polymyxin-meropenem for CRAB (strong recommendation against) 3
• Consider carbapenem combinations: When meropenem MIC ≤8 mg/L for CRE or ≤32 mg/L for CRAB, using high-dose extended-infusion (3-hour) meropenem 55

Common Pitfalls to Avoid

1. Using polymyxins for CNS infections: Extremely poor CSF penetration makes them ineffective
2. Monotherapy with polymyxins for severe infections: Associated with worse outcomes 55
3. Ignoring MIC values: Even "susceptible" organisms may require dose optimization for deep-seated infections
4. Standard dosing for critically ill patients: Augmented renal clearance and altered volumes of distribution require therapeutic drug monitoring when available 5
5. Combining nephrotoxic agents with polymyxins: Significantly increases renal toxicity risk 55
6. Using cefiderocol for CRAB: Conditionally recommended against based on mortality signals 3

Non-Severe or Low-Risk Infections

For non-severe CRPA infections, monotherapy with an active agent is acceptable, chosen individually based on infection source and antimicrobial stewardship principles 3.